Your session is about to expire
← Back to Search
Monoclonal Antibodies
RO7759065 + Atezolizumab for Cancer
Phase 1
Recruiting
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
Must not have
Any history of a Grade 4 immune-mediated adverse event attributed to prior cancer immunotherapy
Women who are pregnant or breastfeeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called RO7759065 in patients with advanced solid tumors. It will evaluate how safe and effective the drug is when given alone or in combination with another drug called at
Who is the study for?
This trial is for patients with advanced, recurrent, or metastatic solid tumors that can't be cured. Participants must meet certain health standards and may have had previous treatments. Specific criteria will determine who can join.
What is being tested?
The study tests RO7759065 alone (Phase Ia) and combined with Atezolizumab (Phase Ib) to assess safety, dosage levels, body response, immune reaction, and initial effectiveness in shrinking or controlling tumor growth.
What are the potential side effects?
Possible side effects include reactions at the injection site, fatigue, nausea, feverish symptoms due to immune system activation by the drugs; exact side effects will be monitored closely during the trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My cancer is advanced, has come back, or spread and cannot be cured.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a severe reaction to previous cancer immunotherapy.
Select...
I am not pregnant or breastfeeding.
Select...
I haven't had any cancer treatment, including chemotherapy, in the last 3 weeks.
Select...
I have active hepatitis B, C, or tuberculosis.
Select...
I have brain metastases that haven't been treated yet.
Select...
I have or had an autoimmune disease or immune deficiency.
Select...
I have had a stem cell or organ transplant from another person.
Select...
I stopped a cancer immunotherapy due to a severe reaction.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Phase Ib: ExpansionExperimental Treatment2 Interventions
Group II: Phase Ib: Dose EscalationExperimental Treatment2 Interventions
Group III: Phase Ia: ExpansionExperimental Treatment1 Intervention
Group IV: Phase Ia: Dose EscalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2016
Completed Phase 3
~5860
Find a Location
Who is running the clinical trial?
Genentech, Inc.Lead Sponsor
1,565 Previous Clinical Trials
569,690 Total Patients Enrolled